Aerie Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€182.48M - Cost of goods sold
€20.06M - Gross profit
€162.42M - SG&A expenses
€110.51M - R&D expenses
€74.70M - EBITDA
-€2.62M - D&A
€17.20M - EBIT
-€19.82M - Interest expenses
€10.23M - EBT
-€30.05M - Tax expenses
€1.13M - Net income
-€31.18M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€453.77K - Changes in working capital
€4.85M - Operating cash flow
€6.11M - Capex
€3.86M - Other investing cash flow
€0.00 - Net investing cash flow
-€15.61M - Total cash dividends paid
€0.00 - Issuance of common stock
€2.07M - Debt repayment
€0.00 - Other financing cash flow
€2.89M - Net financing cash flow
€2.89M - Foreign exchange effects
€0.00 - Net change in cash
-€6.61M - Cash at end of period
€46.14M - Free cash flow
€9.98M
Balance sheet
- Cash and cash equivalents
€46.14M - Cash and short-term investments
€147.10M - Total receivables
€63.02M - Inventory
€39.89M - Other current assets
€8.28M - Total current assets
€258.28M - Property, plant & equipment
€60.61M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€1.47M - Total non-current assets
€62.08M - Total assets
€320.36M - Accounts payable
€7.73M - Short-term debt
€4.16M - Other current liabilities
€41.38M - Total current liabilities
€113.73M - Long-term debt
€283.28M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€2.77M - Total non-current liabilities
€346.50M - Total liabilities
€460.23M - Common stock
€41.79K - Retained earnings
-€1.01B - Other equity
-€684.92K - Total equity
-€139.87M - Total liabilities and shareholders' equity
€320.36M
Company information
- Market capitalization
€0.00 - Employees
376 - Enterprise Value
€223.46M
Company ratios
- Gross margin
-
89.0% Much better than peer group: -74.0% - EBITDA margin
-
-1.4% Much better than peer group: -152,609,903.6% - EBIT margin
-
-10.9% Much better than peer group: -194,397,652.4% - EBT margin
-
-16.5% Much better than peer group: -129,540,986.5% - Net margin
-
-17.1% Much better than peer group: -129,539,853.5% - ROE
-
22.3% Much better than peer group: -12.5% - ROA
-
-9.7% Much better than peer group: -47.1% - Asset turnover
-
57.0% Worse than peer group: 62.1% - FCF margin
-
1.2% Much better than peer group: -76,023,338.5% - FCF yield
0.0% - Efficiency ratio
101.4% - Net sales per employee
-
€485.32K - Net income per employee
-
-€82.92K